Perceptive Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Perceptive Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,441,700	Closed	-$43.4M	–	141
2018 Q3	$43.4M	Buy	2,441,700 +520,000	+27%	+$8.93M	1.16%	27
2018 Q2	$26.5M	Sell	1,921,700 -280,000	-13%	-$3.32M	0.7%	39
2018 Q1	$20M	Buy	2,201,700 +750,000	+52%	+$4.14M	0.56%	46
2017 Q4	$6.21M	Buy	+1,451,700	New	+$6.92M	0.21%	71
2014 Q2	–	Sell	-435,000	Closed	-$10.4M	–	158
2014 Q1	$10.4M	Sell	435,000 -236,300	-35%	-$3.43M	1.09%	30
2013 Q4	$5.23M	Buy	671,300 +252,585	+60%	+$2.79M	0.63%	37
2013 Q3	$5.58M	Buy	418,715 +349,909	+509%	+$5.53M	0.45%	38
2013 Q2	$903K	Buy	+68,806	New	+$928K	0.09%	62

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Perceptive Advisors's ECYT Position: Q4 2018 in Review

Perceptive Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 2,441,700 shares — an estimated $43.4M sold.

Perceptive Advisors first reported a position in ECYT in Q2 2013 and held it in 8 quarters. The position peaked at $43.4M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Perceptive Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Perceptive Advisors sold 2,441,700 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $43.4M.
Perceptive Advisors first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
Perceptive Advisors's Endocyte, Inc. Common Stock position peaked at $43.4M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.